Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received an average recommendation of “Hold” from the twenty-one analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $19.5909.

NTLA has been the subject of several research reports. Wells Fargo & Company lifted their price objective on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Oppenheimer set a $27.00 price target on Intellia Therapeutics in a research report on Friday, November 7th. Evercore set a $8.00 price target on Intellia Therapeutics and gave the company an “in-line” rating in a research note on Tuesday, November 11th. Royal Bank Of Canada raised their price objective on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Finally, Citizens Jmp lifted their target price on Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a report on Tuesday.

Insider Activity

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John M. Leonard sold 34,146 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the sale, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,051 shares of company stock valued at $488,600 in the last ninety days. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Comerica Bank raised its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth approximately $26,000. Blue Bell Private Wealth Management LLC purchased a new position in shares of Intellia Therapeutics during the 3rd quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Intellia Therapeutics in the 3rd quarter valued at $30,000. Finally, Advisory Services Network LLC purchased a new stake in Intellia Therapeutics during the third quarter worth $33,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene‑therapy trial for Intellia — a material de‑risking event that restores clinical momentum for NTLA’s in‑vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near‑term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near‑term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near‑term cost pressure acknowledged, long‑term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near‑term sentiment and give holders a reason to take profits after the run‑up. Canaccord lowers expectations

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $13.15 on Friday. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -3.43 and a beta of 2.10. The stock’s 50-day simple moving average is $12.25 and its 200-day simple moving average is $13.10.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The company had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. Intellia Therapeutics’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period last year, the business earned ($1.27) EPS. As a group, equities analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.